Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pliant Therapeutics Inc
(NQ:
PLRX
)
13.88
+0.63 (+4.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pliant Therapeutics Inc
< Previous
1
2
3
Next >
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
July 15, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
June 13, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 21, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
May 14, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
May 01, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
April 02, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
March 27, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 12, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
February 27, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
February 26, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 04, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
November 13, 2023
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
November 08, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
November 06, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
October 31, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
October 19, 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
October 16, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
September 26, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
September 25, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
September 15, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
September 11, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.